Access policy

We are pursuing new treatments for rare lung disorders such as IPF. Currently, these are experimental unlicensed medicines and, until we have fully evaluated the benefits and risks, we are unable to offer the medicines outside any research setting.

You can read more about our ongoing clinical programs here in our website or learn more on If you would like to speak to someone at Vicore Pharma then please email